health pharma news today obesity drugs glp-1 Giants Bet on Next-Generation Treatments to Sustain Growth The Disruptive Power of Weight
Description
Individual results will vary based on starting weight, age, metabolic health, adherence to post-operative guidelines, and other personal health factors
announced the decision to discontinue the development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for chronic weight management
Can Ozempic Replace Metformin
M.SvalastogaP.MaloneyK
While not approved specifically for weight loss, clinical trials showed average weight reduction of 3-5% of body weight, making it the least potent option in this category for weight management
